Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin

Core Insights - Modus Therapeutics has successfully completed patient enrollment for part 1 of its clinical phase 2a study evaluating sevuparin as a treatment for chronic kidney disease with anemia [1][2] - The study aims to assess the safety and dosing levels of sevuparin in patients with chronic kidney disease (stage 3-5) and healthy volunteers, conducted in Italy [2] - Karolinska Development holds a 66% ownership stake in Modus Therapeutics, indicating significant investment in the company's potential [3] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [4][5] - The company aims to build companies around leading scientists and experienced management teams, co-funded by international investors to enhance the likelihood of success [5][6] - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by a strong global network [6]